Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder that damages nerve cells and causes disability. The condition also is known as Lou Gehrig’s disease, after the famed New York Yankees baseball player who was diagnosed with the disorder in the late 1930s.
Search results for:
Four people with amyotrophic lateral sclerosis (ALS) each experienced a marked slowing in disease progression with COYA 302, an experimental immune-modulating therapy tested in a small proof-of-concept clinical trial, according to Coya Therapeutics, its developer. Based on these findings, Coya is planning to start work on further trials to…
ALS has taught me many life lessons, and a very important one is to never give up. For example, some days I get up, get going, and suddenly notice that one of my body parts isn’t moving as well as the day before. It’s a small, quirky thing, like…
Amylyx Pharmaceuticals is facing a new hurdle — a second round of questions from a European Medicines Agency (EMA) committee — in its quest to have AMX0035 approved as a treatment for amyotrophic lateral sclerosis (ALS) in Europe. The questions, from the Committee for Medicinal Products for…
Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a progressive neurodegenerative disorder that runs in families in about 10% of cases. When more than one person in the same biological family is affected by the disease, it is referred to as familial ALS.
About 90% of cases of amyotrophic lateral sclerosis (ALS), the progressive neurological disorder also known as Lou Gehrig's disease, are characterized as sporadic ALS, meaning they occur spontaneously. The term sporadic in ALS means without a clear pattern, and the individuals with these cases have no known family history of the disease.
Anew Medical‘s targeted gene therapy candidate, ANEW-202, eased multiple mechanisms associated with amyotrophic lateral sclerosis (ALS), leading to improved muscle function and survival in a mouse model of the disease. The gene therapy, licensed on an exclusive worldwide basis from the Autonomous University of Barcelona, in Spain, is…
My husband, Todd, and I enjoy watching chickadees flit from a feeder that hangs from a mountain ash tree behind our house to one of the branches, where they crack the shells and eat the sunflower seeds. “Let Comet out,” Todd told me one morning. “There’s a squirrel in the…
QurAlis has secured $88 million to advance the clinical development of QRL-101 and QRL-201, its lead candidates for amyotrophic lateral sclerosis (ALS). The new series B financing, a second round of funding after the company met certain research milestones, brings the total investment to $143.5 million. The proceeds will…
The Muscular Dystrophy Association (MDA) is hosting its 16th annual MDA Atlanta Night of Hope Gala: A Benefit for ALS Research to raise funds for amyotrophic lateral sclerosis (ALS) research and care. The event will be held 6-11 p.m. EDT March 25 at the InterContinental Buckhead Atlanta. It…